PEG-g-Chitosan Nanoparticles Functionalized with the Monoclonal Antibody OX26 for Brain Drug Targeting

Monsalve, Yuliana; Tosi, Giovanni; Ruozi, Barbara; Belletti, Daniela; Vilella, Antonietta; Zoli, Michèle; Vandelli, Maria Angela; Forni, Flavio; López, Betty L.; Sierra, Ligia

doi:10.2217/nnm.15.29

Cited by 75 publications

(48 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In mice, the highest concentration of gold in the brain was gathered 2 h after IV injection of 20 nm gold ENPs (in comparison with 50 and 70 nm ENPs). Finally, we quote an example of a study in which the authors have cleverly combined several approaches in order to optimize and increase the brain uptake of ENPs [ 54 ]. They have designed pegylated CS ENPs grafted or not grafted with the mAb OX26 (CS-PEG-OX26 or CS-PEG ENPs) as a targeting ligand.…”

Section: Engineered Nanoparticles: Promising Candidates To Tackle mentioning

confidence: 99%

Nanoparticle-Based Strategies to Treat Neuro-Inflammation

Poupot

Bergozza

2018

Materials

View full text Add to dashboard Cite

Neuro-inflammation is a pivotal physio-pathological feature of brain disorders, including neurodegenerative diseases. As such, it is a relevant therapeutic target against which drugs have to be proposed. Targeting neuro-inflammation implies crossing the Blood-Brain Barrier (BBB) to reach the Central Nervous System (CNS). Engineered nanoparticles (ENPs) are promising candidates to carry and deliver drugs to the CNS by crossing the BBB. There are several strategies to design ENPs intended for crossing through the BBB. Herein, we first put nanotechnologies back in their historical context and introduce neuro-inflammation and its consequences in terms of public health. In a second part, we explain how ENPs can get access to the brain and review this area by highlighting recent papers in the field. Finally, after pointing out potential guidelines for preclinical studies involving ENPs, we conclude by opening the debate on the questions of nanosafety and toxicity of these ENPs and in particular on ecotoxicity related to regulatory issues and public concerns.

show abstract

Section: Engineered Nanoparticles: Promising Candidates To Tackle mentioning

confidence: 99%

Nanoparticle-Based Strategies to Treat Neuro-Inflammation

Poupot

Bergozza

2018

Materials

View full text Add to dashboard Cite

show abstract

“…For instance, some ligands such as transferrin (Tf), Apolipoprotein (Apo) E, B, A, and antibodies (Tf receptor or OX26) on the surface of NPs have been shown to pass through the BBB and allow targeted delivery of carriers into the brain parenchyma via receptor-mediated endocytosis [90][91][92][93][94][95][96]. For example, PEGylated albumin or chitosan (CS) NPs coupled with OX-26 were proposed as a potential candidate for targeted brain delivery [97,98]. The main mechanism for the delivery of these NPs through the BBB is receptor-mediated transport endocytosis.…”

Section: Development Of the Nanoparticulate Systems: From Simple To Tmentioning

confidence: 99%

Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics

et al. 2020

View full text Add to dashboard Cite

The blood–brain barrier (BBB) acts as a barrier to prevent the central nervous system (CNS) from damage by substances that originate from the blood circulation. The BBB limits drug penetration into the brain and is one of the major clinical obstacles to the treatment of CNS diseases. Nanotechnology-based delivery systems have been tested for overcoming this barrier and releasing related drugs into the brain matrix. In this review, nanoparticles (NPs) from simple to developed delivery systems are discussed for the delivery of a drug to the brain. This review particularly focuses on polymeric nanomaterials that have been used for CNS treatment. Polymeric NPs such as polylactide (PLA), poly (D, L-lactide-co-glycolide) (PLGA), poly (ε-caprolactone) (PCL), poly (alkyl cyanoacrylate) (PACA), human serum albumin (HSA), gelatin, and chitosan are discussed in detail.

show abstract

“…Fluorescently labeled chitosan (CS) NPs conjugated with PEG bearing the OX26 mAbs to take advantage of receptor-mediated transport across the BBB [64,65] was obtained after i.v. administration in mice.…”

Section: Biodistributionmentioning

confidence: 99%

“…In similar experiments, the accumulation and tropism of the same kind of NPs were assessed after i.v. administration in mice by means of confocal microscopy, assessing preferential accumulation of these NPs in hippocampal areas [65]. Another example of labeled components, as proof-of-concept, could be recovered by an experiment of Sun and colleagues, using PS-80 coated PLA NPs with FITC-dextran.…”

Section: Biodistributionmentioning

confidence: 99%